The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 350:1945-1952 May 6, 2004 Number 19
NextNext

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
Jacques Bernier, M.D., Ph.D., Christian Domenge, M.D., Mahmut Ozsahin, M.D., Ph.D., Katarzyna Matuszewska, M.D., Jean-Louis Lefèbvre, M.D., Richard H. Greiner, M.D., Jordi Giralt, M.D., Philippe Maingon, M.D., Frédéric Rolland, M.D., Michel Bolla, M.D., Francesco Cognetti, M.D., Jean Bourhis, M.D., Anne Kirkpatrick, M.Sc., Martine van Glabbeke, Ir., M.Sc., for the European Organization for Research and Treatment of Cancer Trial 22931

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Saunders, M. I.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer.

Methods After undergoing surgery with curative intent, 167 patients were randomly assigned to receive radiotherapy alone (66 Gy over a period of 6 1/2 weeks) and 167 to receive the same radiotherapy regimen combined with 100 mg of cisplatin per square meter of body-surface area on days 1, 22, and 43 of the radiotherapy regimen.

Results After a median follow-up of 60 months, the rate of progression-free survival was significantly higher in the combined-therapy group than in the group given radiotherapy alone (P=0.04 by the log-rank test; hazard ratio for disease progression, 0.75; 95 percent confidence interval, 0.56 to 0.99), with 5-year Kaplan–Meier estimates of progression-free survival of 47 percent and 36 percent, respectively. The overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group (P=0.02 by the log-rank test; hazard ratio for death, 0.70; 95 percent confidence interval, 0.52 to 0.95), with five-year Kaplan–Meier estimates of overall survival of 53 percent and 40 percent, respectively. The cumulative incidence of local or regional relapses was significantly lower in the combined-therapy group (P=0.007). The estimated five-year cumulative incidence of local or regional relapses (considering death from other causes as a competing risk) was 31 percent after radiotherapy and 18 percent after combined therapy. Severe (grade 3 or higher) adverse effects were more frequent after combined therapy (41 percent) than after radiotherapy (21 percent, P=0.001); the types of severe mucosal adverse effects were similar in the two groups, as was the incidence of late adverse effects.

Conclusions Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.


Source Information

From the Department of Radio-Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland (J. Bernier); the Department of Radio-Oncology, Institut Gustave Roussy, Villejuif, France (C.D., J. Bourhis); the Department of Radio-Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (M.O.); the Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (K.M.); the Ear, Nose, and Throat Department, Centre O. Lambret, Lille, France (J.-L.L.); the Department of Radio-Oncology, Inselspital, Bern, Switzerland (R.H.G.); the Department of Radio-Oncology, Hospital General Vall d'Hebron, Barcelona, Spain (J.G.); the Department of Radio-Oncology, Centre G.F. Leclerc, Dijon, France (P.M.); the Department of Radio-Oncology, Centre R. Gauducheau, St. Herblain, France (F.R.); the Department of Radio-Oncology, Centre Hospitalier Universitaire A. Michallon, Grenoble, France (M.B.); Istituto Regina Elena, Rome (F.C.); and the European Organization for Research and Treatment of Cancer Data Center, Brussels (A.K., M.G.).

Address reprint requests to Dr. Bernier at the Department of Radio-Oncology, San Giovanni Hospital, Oncology Institute of Southern Switzerland, CH-6504 Bellinzona, Switzerland, or at jacques.bernier{at}hcuge.ch.

Full Text of this Article


Related Letters:

Treatment of Advanced Head and Neck Cancer
Fortin A., Audet N., Caouette R., Yalçyn B., Büyükçelik A., Utkan G., Sonpavde G., Cooper J. S., Forastiere A. A., Jacobs J., Bernier J., the European Organization for Research and Treatment of Cancer
Extract | Full Text | PDF  
N Engl J Med 2004; 351:829-831, Aug 19, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.